Copy Link Print Information

Rimegepant hemisulfate

(Synonyms: BMS-927711 hemisulfate; BHV-3000 hemisulfate)
12 Cited Publications
Customer Review

Based on 12 publication(s) in Google Scholar

Rimegepant (BMS-927711) hemisulfate is a potent, orally active, selective and competitive calcitonin gene-related peptide (CGRP) receptor antagonist with a Ki of 0.027 nM and an IC50 of 0.14 nM for hCGRP receptor. Rimegepant hemisulfate can be used for migraine research.

For research use only. We do not sell to patients.

  • CAS No.: 1642783-82-1
  • Formula: C28H30F2N6O7S
  • Molecular Weight:583.60
  • Storage:

    Please store the product under the recommended conditions in the Certificate of Analysis.

  • Rimegepant hemisulfate Chemical Structure
    Rimegepant hemisulfate Chemical Structure
  • Experimental Validation Results for Rimegepant hemisulfate
  • Experimental Validation Results for Rimegepant hemisulfate
  • Experimental Validation Results for Rimegepant hemisulfate
  • Experimental Validation Results for Rimegepant hemisulfate
  • Experimental Validation Results for Rimegepant hemisulfate
  • Experimental Validation Results for Rimegepant hemisulfate
  • Experimental Validation Results for Rimegepant hemisulfate
CAS No.: 1642783-82-1
Size
Price
Stock
Quantity
Amount: USD 0.00
Please select quantity
or
or

* Please select Quantity before adding items.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of Rimegepant hemisulfate:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Find Your Local Distributor Your local distributor: Hycultec GmbHHycultec
  • Biological Activity
  • Chemical Information
  • Purity & Documentation
  • References
  • Help & FAQs
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Rimegepant hemisulfate

More
Customer Validation & Images
Histological Imaging/StainingFlow CytometryIn Vivo Efficacy StudyIFCell Proliferation/Viability Assay
  • Histological Imaging/Staining
  • In Vivo Efficacy Study
  • Flow Cytometry
  • In Vivo Efficacy Study
  • Histological Imaging/Staining
  • IF
  • Cell Proliferation/Viability Assay
Keywords
MOQ
Minimum order quantity
100 mg

Get Quote In-stock

Other size
Get Quote
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Sign In
Register
Sign in to MedChemExpress
Register New Account

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • Rimegepant hemisulfate Chemical Structure
    Rimegepant hemisulfate Chemical Structure
    1/16
  • 1/16

    Rimegepant hemisulfate purchased from MedChemExpress. Usage Cited in: Nature. 2025 Apr;640(8059):802-810. [Abstract]

    Customer Validation
     Representative images of MNU-induced dysplasia from CNO-treated mice with or without Rimegepant administration were presented. CNO-activated mice treated with a diet containing Rimegepant (a CGRP antagonist; 10 mg/kg; mixed into the AIN-76A mouse chow) showed reduced MNU-induced tumour development compared with the untreated controls.

  • 1/16

    Rimegepant hemisulfate purchased from MedChemExpress. Usage Cited in: Nature. 2025 Apr;640(8059):802-810. [Abstract]

    Customer Validation
     Representative images of syngeneic orthotopic tumours from CNO-treated mice with or without Rimegepant (a CGRP antagonist; 10 mg/kg; mixed into the AIN-76A mouse chow) administration were shown. Nociceptive neuronal activation resulted in significantly increased tumour volume, which was inhibited by Rimegepant treatment.

  • 1/16

    Rimegepant hemisulfate purchased from MedChemExpress. Usage Cited in: Free Radic Biol Med. 2025 Dec 24:245:18-29. [Abstract]

    Customer Validation
     Reduced proliferative responsiveness of Tregs isolated from patients with active vitiligo to CGRP was observed. CD4 + CD25 high CD127 dim Tregs were sorted by flow cytometry and cultured for 72 h in the presence of Rimegepant (1 μM). DMSO was used as the vehicle control. Representative scatter plots of Tregs from healthy controls (upper panels) and from patients with active vitiligo (lower panels) were shown.

  • 1/16

    Rimegepant hemisulfate purchased from MedChemExpress. Usage Cited in: Free Radic Biol Med. 2025 Dec 24:245:18-29. [Abstract]

    Customer Validation
     Effects of Rimegepant (0.2 mg/mouse/day; oral gavage; three times weekly for 3 weeks) on depigmentation in the tail skin of vitiligo model mice were investigated. Representative macroscopic and Wood's lamp images of tail skin from each group were shown. White arrows indicated depigmented areas, and quantification of depigmented areas was shown on the right. Rimegepant partially reversed CGRP-induced vitiligo progression.

  • 1/16

    Rimegepant hemisulfate purchased from MedChemExpress. Usage Cited in: Free Radic Biol Med. 2025 Dec 24:245:18-29. [Abstract]

    Customer Validation
     X-gal staining and immunofluorescence were performed on tail skin sections from each group. Upper panels: X-gal staining visualized MCs (black arrows); black dashed lines indicated borders between depigmented and normally pigmented areas. Lower panels: Immunofluorescence staining of FOXP3+ Tregs (green) with nuclei labeled by DAPI (blue); white dashed lines denoted the dermal-epidermal junction, and white arrows indicated FOXP3+ Tregs. Rimegepant (0.2 mg/mouse/day; oral gavage; three times weekly for 3 weeks) partially reversed CGRP-induced vitiligo progression and restored Treg numbers.

  • 1/16

    Rimegepant hemisulfate purchased from MedChemExpress. Usage Cited in: Cell Metab. 2022 Dec 6;34(12):1999-2017.e10. [Abstract]

    Customer Validation
     Treated OSCCPDEs with TG CM significantly increased the proportion of Ki67+ cancer cells under low-glucose culture and upon 2-DG treatment, which was antagonized by Rimegepant via antagonism of CGRP-CLR signaling.

  • 1/16

    Rimegepant hemisulfate purchased from MedChemExpress. Usage Cited in: Cell Metab. 2022 Dec 6;34(12):1999-2017.e10. [Abstract]

    Customer Validation
     In vitro Cal27 cell growth of indicated cancer cells upon Rimegepant treatment for 48 hrs (n=4 biological replicates per group).

  • Rimegepant hemisulfate